Back to top

Forte Biosciences initiated with an Overweight at Barclays

Barclays initiated coverage of Forte Biosciences (FBRX) with an Overweight rating and $74 price target The firm views the company’s CD122 as a “com...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Forte Biosciences, Inc. (FBRX)